Year archive

EMYRIA LIMITED — 2022 filings

All 72 regulatory filings released by EMYRIA LIMITED (EMD) in 2022, sourced directly from the official regulator.

72 Filings

2022 Period

2022 filings (72)

Filing	Released	Lang
Letter to Shareholders/Notice of General Meeting/Proxy Form 22 pages 1.1MB Proxy Solicitation & Information Statement	2022-12-15	English
Upcoming Emyria CEO Webinars 2 pages 175.2KB Investor Presentation	2022-12-06	English
Application for quotation of securities - EMD 8 pages 29.9KB Share Issue/Capital Change	2022-12-06	English
Notice under section 708A(5)(e) of the Corporations Act 2 pages 286.7KB Share Issue/Capital Change	2022-12-06	English
Change of Director's Interest Notice 2 pages 251.6KB Director's Dealing	2022-11-27	English
Emyria accepted into National Institutes of Health Program 3 pages 647.5KB Regulatory Filings	2022-11-27	English
Notification regarding unquoted securities - EMD 8 pages 30.0KB Share Issue/Capital Change	2022-11-24	English
Notification regarding unquoted securities - EMD 9 pages 32.9KB Share Issue/Capital Change	2022-11-24	English
Application for quotation of securities - EMD 8 pages 29.6KB Capital/Financing Update	2022-11-22	English
Notification regarding unquoted securities - EMD 9 pages 33.6KB Share Issue/Capital Change	2022-11-22	English
Investor Presentation 47 pages 10.4MB Investor Presentation	2022-11-22	English
Placement completion and secondary trading notice 3 pages 536.1KB Capital/Financing Update	2022-11-22	English
Notification of cessation of securities - EMD 5 pages 25.5KB Share Issue/Capital Change	2022-11-17	English
Amended Constitution 58 pages 536.1KB Governance Information	2022-11-16	English
Emyria completes $3m placement 3 pages 549.3KB Capital/Financing Update	2022-10-30	English
Proposed issue of securities - EMD 6 pages 30.0KB Capital/Financing Update	2022-10-30	English
Proposed issue of securities - EMD 6 pages 31.3KB Capital/Financing Update	2022-10-30	English
Proposed issue of securities - EMD 7 pages 32.4KB Capital/Financing Update	2022-10-30	English
Appendix 4C - Quarterly 10 pages 859.9KB Interim / Quarterly Report	2022-10-30	English
Trading Halt 2 pages 692.5KB Capital/Financing Update	2022-10-26	English
Results of Meeting 3 pages 542.1KB Declaration of Voting Results & Voting Rights Announcements	2022-10-24	English
Emyria and UWA expand unique MDMA-inspired analogue library 2 pages 543.9KB Regulatory Filings	2022-10-17	English
MDMA-inspired drug discovery presentation 32 pages 5.5MB Investor Presentation	2022-10-12	English
Emyria Investor Webinar - October 13 2 pages 315.9KB Investor Presentation	2022-10-09	English
Emyria expands clinical sites for EMD-RX5 Phase 3 trial 5 pages 309.9KB Capital/Financing Update	2022-09-25	English
Notice of Annual General Meeting/Proxy Form 46 pages 1.1MB AGM Information	2022-09-22	English
Letter to Shareholders - Annual General Meeting 3 pages 895.2KB AGM Information	2022-09-22	English
Emyria commences US preclinical program for MDMA library 5 pages 533.8KB Regulatory Filings	2022-09-18	English
Annual General Meeting 2 pages 295.7KB AGM Information	2022-08-30	English
Annual Report to Shareholders 87 pages 1.7MB Annual Report	2022-08-29	English
Appendix 4E and Annual Report 89 pages 2.0MB Annual Report	2022-08-28	English
Appendix 4G 13 pages 295.2KB Regulatory Filings	2022-08-28	English
Positive results received for Emyrias MDMA-inspired program 5 pages 318.8KB Regulatory Filings	2022-08-17	English
Notification regarding unquoted securities - EMD 9 pages 32.1KB Share Issue/Capital Change	2022-08-16	English
Emyria receives ethics approval for EMD-RX5 Phase 3 trial 5 pages 155.9KB Regulatory Filings	2022-08-15	English
Preclinical studies initiated for MDMA-inspired analogues 4 pages 157.1KB Regulatory Filings	2022-08-03	English
Appendix 4C - Quarterly 11 pages 777.2KB Interim / Quarterly Report	2022-07-27	English
Emyria expands drug candidate library inspired by MDMA 4 pages 161.6KB Regulatory Filings	2022-07-17	English
Notification regarding unquoted securities - EMD 9 pages 32.1KB Share Issue/Capital Change	2022-06-08	English
Drug development webinar presentation 32 pages 7.1MB Investor Presentation	2022-05-31	English
Emyria expands MDMA analogue program with UWA 5 pages 1.2MB Capital/Financing Update	2022-05-30	English
Emyria Investor Webinar, June 1st 2 pages 144.8KB Regulatory Filings	2022-05-29	English
EMD-RX5 demonstrates excellent safety and bioavailability 6 pages 1.2MB Capital/Financing Update	2022-05-24	English
Trading Halt 2 pages 249.5KB Regulatory Filings	2022-05-22	English
Further positive MDMA analogue screening results received 4 pages 706.1KB Regulatory Filings	2022-05-09	English
Appendix 4C - Quarterly 12 pages 990.1KB Interim / Quarterly Report	2022-04-26	English
Change of Director's Interest Notice MW 2 pages 250.6KB Director's Dealing	2022-04-19	English
Results of Meeting 3 pages 130.3KB Declaration of Voting Results & Voting Rights Announcements	2022-04-19	English
EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial 5 pages 459.7KB Regulatory Filings	2022-04-13	English
Clinitrials to lead multi-site Phase 3 trial for EMD-RX5 3 pages 144.8KB Regulatory Filings	2022-04-12	English
Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial 5 pages 459.5KB Regulatory Filings	2022-04-06	English
Broker Briefing Presentation 35 pages 7.3MB Investor Presentation	2022-03-23	English
Emyria to present webinar, March 24th 2 pages 144.6KB Investor Presentation	2022-03-22	English
Addendum to Notice of Meeting and Proxy Form 12 pages 833.7KB AGM Information	2022-03-17	English
Letter to Shareholders - Adjourned General Meeting 4 pages 916.7KB Proxy Solicitation & Information Statement	2022-03-17	English
EMD-RX5 program advancing Phase 1 clinical trials underway 5 pages 258.3KB Capital/Financing Update	2022-03-16	English
Emyria launches second ultra-pure CBD capsule 5 pages 258.3KB Regulatory Filings	2022-03-16	English
Recruitment commenced for EMD-RX5 Phase 1 Study 3 pages 139.2KB Regulatory Filings	2022-03-08	English
Hidden Gems Webinar Presentation 28 pages 5.5MB Investor Presentation	2022-03-03	English
Ethics approval received for EMD-RX5 Phase 1 Study 3 pages 136.0KB Capital/Financing Update	2022-03-02	English
Emyria to present at Hidden Gems Webinar March 4th 2 pages 138.9KB Investor Presentation	2022-03-01	English
Half Yearly Report and Accounts 35 pages 890.1KB Interim / Quarterly Report	2022-02-27	English
General Meeting Adjourned - Letter to Shareholders 1 Proxy Solicitation & Information Statement	2022-02-21	English
Emyria grows its novel MDMA-analogue library 3 pages 138.3KB Regulatory Filings	2022-02-21	English
Application for quotation of securities - EMD 8 pages 29.1KB Share Issue/Capital Change	2022-02-13	English
Release of securities from escrow 1 page 272.8KB Capital/Financing Update	2022-02-03	English
Appendix 4C - Quarterly 11 pages 583.9KB Interim / Quarterly Report	2022-01-27	English
Application for quotation of securities - EMD 8 pages 29.6KB Capital/Financing Update	2022-01-27	English
Notice under section 708A(5)(e) of the Corporations Act 2 pages 286.7KB Capital/Financing Update	2022-01-27	English
Notice of General Meeting/Proxy Form 23 pages 863.3KB Proxy Solicitation & Information Statement	2022-01-20	English
Letter to Shareholders - General Meeting 3 pages 898.5KB Proxy Solicitation & Information Statement	2022-01-20	English
Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD 4 pages 274.8KB Regulatory Filings	2022-01-19	English